Literature DB >> 31106014

Mucous Membrane Pemphigoid-Associated Malignancies: Case Series and a Brief Overview of the Literature.

Michelangelo La Placa1, Riccardo Balestri1, Federico Tartari1, Andrea Sechi1, Francesca Ferrara1, Camilla Loi1, Annalisa Patrizi1, Federico Bardazzi1.   

Abstract

BACKGROUND: Mucous membrane pemphigoid (MMP) is a heterogeneous group of blistering disorders affecting the mucosae with or without skin involvement, characterized by the presence of autoantibodies to components of the basement membrane zone, including the bullous pemphigoid antigen BP180 and β4 integrin. Current literature has shown that a minority of patients present circulating antibodies to laminin-332 and this population seems to be associated with a relatively high risk of malignancy.
OBJECTIVE: To present our personal case series of patients with MMP-associated malignancy from a dermatology university hospital.
METHODS: Twenty-two patients affected by MMP were seen in the period between 2001 and 2016; in 4 patients (18%) an associated cancer was detected.
RESULTS: These patients were 2 men and 2 women, with a mean age of 69.7 years (range, 48-83). The associated malignancies included a breast cancer, a pancreatic adenocarcinoma, a metastatic laryngeal carcinoma, and a hepatic carcinoma. All patients had negative results for both BP180 and laminin-332 autoantibodies.
CONCLUSION: We confirm that MMP patients have a relatively high possibility of developing a solid cancer, but the autoantibody detection is not mandatory and is probably correlated with the severity of the disease.

Entities:  

Keywords:  adenocarcinoma; anti-epiligrin; autoimmune bullous disorders; blistering diseases; cicatricial pemphigoid; laminin-332; laminin-5; malignancy; mucous membrane pemphigoid; paraneoplastic pemphigus

Year:  2019        PMID: 31106014      PMCID: PMC6502303          DOI: 10.5826/dpc.0902a07

Source DB:  PubMed          Journal:  Dermatol Pract Concept        ISSN: 2160-9381


  38 in total

1.  Remission of antiepiligrin (laminin-5) cicatricial pemphigoid after excision of gastric carcinoma.

Authors:  K Uchiyama; Y Yamamoto; K Taniuchi; C Matsui; Y Fushida; Y Shirao
Journal:  Cornea       Date:  2000-07       Impact factor: 2.651

2.  Cicatricial pemphigoid in non-Hodgkin's lymphoma.

Authors:  J F Shannon; A Mackenzie-Wood; G Wood; D Goldstein
Journal:  Intern Med J       Date:  2003-08       Impact factor: 2.048

3.  Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human beta4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model.

Authors:  K C Bhol; J E Colon; A R Ahmed
Journal:  J Invest Dermatol       Date:  2003-04       Impact factor: 8.551

Review 4.  The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.

Authors:  Lawrence S Chan; A Razzaque Ahmed; Grant J Anhalt; Wolfgang Bernauer; Kevin D Cooper; Mark J Elder; Jo-David Fine; C Stephen Foster; Reza Ghohestani; Takashi Hashimoto; Thanh Hoang-Xuan; Gudula Kirtschig; Neil J Korman; Susan Lightman; Francina Lozada-Nur; M Peter Marinkovich; Bartly J Mondino; Catherine Prost-Squarcioni; Roy S Rogers; Jane F Setterfield; Dennis P West; Fenella Wojnarowska; David T Woodley; Kim B Yancey; Detlef Zillikens; John J Zone
Journal:  Arch Dermatol       Date:  2002-03

5.  Anti-epiligrin cicatricial pemphigoid and relative risk for cancer.

Authors:  C A Egan; Z Lazarova; T N Darling; C Yee; T Coté; K B Yancey
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

6.  Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5.

Authors:  K Taniuchi; M Takata; C Matsui; Y Fushida; K Uchiyama; T Mori; S Kawara; K B Yancey; K Takehara
Journal:  Br J Dermatol       Date:  1999-04       Impact factor: 9.302

7.  Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.

Authors:  E Schmidt; K Obe; E B Bröcker; D Zillikens
Journal:  Arch Dermatol       Date:  2000-02

Review 8.  Paraneoplastic cicatricial pemphigoid.

Authors:  J Setterfield; P J Shirlaw; Z Lazarova; B M Bryant; B S Bhogal; K Harman; S J Challacombe; M M Black
Journal:  Br J Dermatol       Date:  1999-07       Impact factor: 9.302

9.  Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations.

Authors:  Conleth A Egan; Zelmira Lazarova; Thomas N Darling; Carole Yee; Kim B Yancey
Journal:  Medicine (Baltimore)       Date:  2003-05       Impact factor: 1.889

10.  Anti-epiligrin cicatricial pemphigoid: a case associated with gastric carcinoma and features resembling epidermolysis bullosa acquisita.

Authors:  W Fujimoto; A Ishida-Yamamoto; R Hsu; Y Nagao; H Iizuka; K B Yancey; J Arata
Journal:  Br J Dermatol       Date:  1998-10       Impact factor: 9.302

View more
  2 in total

1.  A Probing of the Issue of Detecting IgG, IgG4 and IgA Antibodies to Laminin 332 Epitopes in Mucous Membrane Pemphigoid: A Clinical-Laboratory Experience of a Single Central European University Dermatology Department.

Authors:  Justyna Gornowicz-Porowska; Magdalena Jałowska; Agnieszka Seraszek-Jaros; Monika Bowszyc-Dmochowska; Elżbieta Kaczmarek; Marian Dmochowski
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-04-27

2.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.